A clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer. We were formed in 2009 by Edwin J. Thomas, our chief executive officer and chairman, who through his extensive prior experience as a C-suite executive in several biopharmaceutical companies saw first-hand the need and commercial opportunity for therapies for rare, life threatening diseases with unmet needs.
